Nanoluciferase reporter preserves immunocompetent glioma model fidelity while facilitating longitudinal molecular imaging
Victorio, C. B. L.; Novera, W.; Ganasarajah, A.; Ong, J. L.; Gupta, S.; Ooi, E. E.; Petersen, S.; Msallam, R.; Chacko, A.-M.
Show abstract
Glioblastoma studies employ syngeneic orthotopic models to preserve tumor-immune interactions, but intracranial tumor burden is challenging to monitor longitudinally. Bioluminescence imaging enables non-invasive assessment, although reporter immunogenicity may compromise model fidelity. We engineered murine GL261 glioma cells to stably express nanoluciferase (NLuc) and compared them with parental GL261 (WT) and GL261 cells expressing red-shifted firefly luciferase (Red-FLuc). In vitro, GL261-NLuc retained growth kinetics and morphology comparable to GL261-WT and produced >100-fold stronger bioluminescence than GL261-Red-FLuc. In immunocompetent mice, GL261-NLuc formed lethal brain tumors with survival and tumor histopathology, immune profile, and response patterns to experimental oncolytic virus therapy broadly resembling GL261-WT. In contrast, GL261-Red-FLuc tumors regressed and exhibited heightened inflammation and increased infiltration of activated CD8+ T-cells. Longitudinal imaging of GL261-NLuc tumors detected treatment-associated changes in growth kinetics not captured by survival alone. These establish GL261-NLuc as a practical reporter for longitudinal immunocompetent glioblastoma studies amenable to immunotherapy evaluations.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- MRI-Guided Focused Ultrasound Blood-Brain Barrier Opening Increases Drug Delivery and Efficacy in a Diffuse Midline Glioma Mouse Model 92%
- Tumor Edge-to-Core Transition Promotes Malignancy in Primary-to-Recurrent Glioblastoma Progression in a PLAGL1/CD109-mediated mechanism 92%
- Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1 90%
Similar papers in this journal
- An ex vivo functional biomarker of treatment response in pediatric low-grade glioma 94%
- Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma 93%
- Injectable diblock copolypeptide hydrogel provides platform to maintain high local concentrations of taxol and local tumor control 93%
Similar papers in this journal
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 93%
- A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy 91%
- Functional repair after ischemic injury through high efficiency in situ astrocyte-to-neuron conversion 91%
Similar papers in this journal
- Acquired and intrinsic resistance to vemurafenib in BRAFV600E-driven melanoma brain metastases 90%
- Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates 88%
- miRNA profiling of primate cervicovaginal lavage and extracellular vesicles reveals miR-186-5p as a potential retroviral restriction factor in macrophages 86%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.